NCT00003362View on ClinicalTrials.gov

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 1998

Primary Completion Date

February 28, 2001

Study Completion Date

February 28, 2001

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

QS21

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

sargramostim

BIOLOGICAL

tyrosinase peptide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00003362 - Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter